Key Drivers
- Very strong liquidity
- Low capital returns
- Rich valuation
AIAI Summary
RGEN has shifted from a pure “growth at any price” story to one where near‑term cash generation and diversified revenue validate the thesis, but the stock now prices in meaningful margin and ROIC improvement—so the investment is only attractive if management can demonstrably convert analytics/services revenue into sustained operating‑leverage and higher ROIC; otherwise rich multiples and large intangibles leave downside risk from earnings misses or impairments. Monitor quarterly margin conversion, SG&A leverage post‑M&A, and any signs of intangible impairment as the specific catalysts that will make this a buy or a sell.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very strong liquidity
- •Low capital returns
- •Rich valuation
Repligen has very strong liquidity, positive free cash flow and healthy gross/EBITDA margins but weak ROE/ROA, large intangibles, modest asset efficiency and appears richly valued.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Multi-test support
- •Elevated downside risk
Stock is in a clear short-term downtrend over the last month (≈‑16% from $135.68 to $113.88) testing a multi-test support band near $113–$116 that must hold to avoid further downside.
~16% decline from $135.68 to $113.88 over the last month, signaling increased volatility
Sentiment & News
Key News Insights:
- •Earnings beat
- •Revenue growth
- •Institutional inflows
Repligen beat Q4 EPS and delivered 18% revenue growth, issued 2026 guidance and saw rising institutional interest with broadly positive analyst reaction.
The earnings beat, forward guidance and active investor outreach should bolster sentiment and near-term stock momentum
Similar Companies in Healthcare
Other companies in the same sector with AI ratings